Name
bluebird bio
Company Description
Bluebird bio's gene therapy shows promise against beta-thalassemia
Two patients with beta-thalassemia have not needed transfusions for at least five months after treatment with the gene therapy LentiGlobin, according to a report from bluebird bio. Two patients who received the therapy in a previous
Two patients with beta-thalassemia have not needed transfusions for at least five months after treatment with the gene therapy LentiGlobin, according to a report from bluebird bio. Two patients who received the therapy in a previous
Address
215 First Street
3rd floor
Cambridge, MA 02141
United States
3rd floor
Cambridge, MA 02141
United States